Pyridoxamine Dihydrochloride

Summary

Pyridoxamine Dihydrochloride (CHEMBL4298078) is a phase-3 clinical-stage unknown; indicated across 1 condition including diabetic kidney disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298078
Name	Pyridoxamine Dihydrochloride
Type	Unknown
Max phase	3

Also known as: NSC-21278, Pyridorin, Pyridoxamine dihydrochloride, Pyridoxamine hcl, Pyridoxamine hydrochloride, Pyridoxamine, monohydrochloride, PYRIDOXAMINE DIHYDROCHLORIDE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
diabetic kidney disease	3	MONDO:0005016	EFO:0000401

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02156843	PHASE3	TERMINATED	Pyridorin in Diabetic Nephropathy
NCT00734253	PHASE2	COMPLETED	Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes
NCT03778580	Not specified	COMPLETED	Advanced Glycation Endproducts and Bone Material Strength in T2D Treated With Pyridoxamine

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).